MetalloBio

The sustained efforts of our team have supported a recent slew of granted patents, expanding our intellectual property portfolio.

For the full story:
www.metallobio.com/newsandevent...

Career pathway tracker | Royal Society Results from a major alumni survey of the University Research Fellowship and Dorothy Hodgkin Fellowships.

As a previous recipient of multiple Royal Society Fellowships, Professor Jim Thomas has been recently featured in their publications.
To see full details: royalsociety.org/grants/caree...

Scientific Advisory Group | |

MetalloBio is pleased to announce the establishment of their Scientific Advisory Group. When conducting novel research it is imperative to seek the counsel of those with tenure in the field. They shall drive innovation and inform our scientific strategies.

www.metallobio.com/newsandevent...

BioTrinity 2025 | OBN (UK) Ltd‌ BioTrinity is OBN's industry leading life sciences conference, designed to catalyse growth across the industry.

MetalloBio shall be represented at Biotrinity by our CEO Michael Murray. Conferences, such as this, are integral to the growth and development of MetalloBio.

obn.glueup.com/event/biotri...

#AMR #Untreatableinfections #GlobalHealth

MetalloBio is pleased to announce the appointment of Dr Eddy Littler as Chairman of the Board. Extensive experience will be important in helping to guide MetalloBio’s growth.

www.metallobio.com/newsandevent...

Over the last year MetalloBio has secured investment and a significant grant from Innovate UK. Our team and peers have conducted studies with promising results, and solving technical challenges has put us in good stead for 2025. In total £700,000 of equity finance was raised, supporting our future.

Don't invest unless you're prepared to lose all the money you invest.
#crowdfunding #untreatableinfection #investment #innovation #SuperBugs
europe.republic.com/metallobio?i...

Don't invest unless you're prepared to lose everything you invest.
Complicated infections are predicted to grow substantially in global market value by 2030. Our #R&D is aimed at overcoming #AMR, this impacts every existing antibiotic. It's a significant market.
europe.republic.com/metallobio/s...

Don’t invest unless you’re prepared to lose all the money you invest.
How do we compete with bigger companies and drive value creation? There are five key strengths that we have as a company that builds our value.

#antibioticresistantinfections
europe.republic.com/metallobio/s...

The #EU has just announced a €40 million p.a. deal with Menarini. To understand how this improves commercial prospects for #antibiotics developers request our Pitch Deck.

ted.europa.eu/en/notice/-/...

Don't invest unless you're prepared to lose all the money you invest.
In both computer software and #bacterialinfections when an issue arises finding the root cause takes time and work.
We wish to begin treating these issues before they become overwhelming.

europe.republic.com/metallobio/s...

Don’t invest unless you’re prepared to lose all the money you invest.
MetalloBio has now amassed over 500 investors. Each milestone we hit in funding, pushes our #R&D further which increases the equity value.
Investing helps drive progress forward.

europe.republic.com/metallobio/s...

Metallobio When investing, capital is at risk. MetalloBio is an antimicrobials company, designing and testing completely new types of antibiotic drugs.

Don’t invest unless you're prepared to lose all the money you invest.

Our funding drives the pace of our #R&D, but it cannot run forever
After midnight on Wednesday 18th Dec our fundraising closes.
Join us whilst there is still time

europe.republic.com/metallobio?i...

Metallobio When investing, capital is at risk. MetalloBio is an antimicrobials company, designing and testing completely new types of antibiotic drugs.

Don't invest unless you're prepared to lose all the money you invest.
Our experienced Finance Director, and incredible research scientists' relentless work have ensured that we use funds cannily to conduct R&D. Invest today to see how much we can accomplish.
europe.republic.com/metallobio?i...

Don’t invest unless you’re prepared to lose all the money you invest.
What was good for Merck, is good for us. MetalloBio aims to provide solutions for patients and, all being well, profits shall follow. #AMR #HealthForAll
europe.republic.com/metallobio?i...

Don't invest unless you're prepared to lose all the money you invest.
A message from our Executive Chairman and CEO Michael Murray post #GenesisLondon24 conference.

#AntimicrobialResistance #crowdfunding
europe.republic.com/metallobio/s...

Metallobio When investing, capital is at risk. MetalloBio is an antimicrobials company, designing and testing completely new types of antibiotic drugs.

Don’t invest unless you’re willing to lose all the money you invest.

Our #R&D is directly funded by our investors, every pound counts. We have extended our first fundraising target, with the aim of conducting more antimicrobial testing. #crowdfunding #AMR

europe.republic.com/metallobio/s...

Metallobio When investing, capital is at risk. MetalloBio is an antimicrobials company, designing and testing completely new types of antibiotic drugs.

Don’t invest unless you’re prepared to lose all the money you invest.
We have entered an overfunding stage on our Seedrs campaign. Thank you! Those who haven't invested yet, there is now an additional 6 days to invest, each pound helps us fight against #AMR .

europe.republic.com/metallobio/s...

Metallobio When investing, capital is at risk. MetalloBio is an antimicrobials company, designing and testing completely new types of antibiotic drugs.

The MetalloBio crowdfunding campaign is only 3 days from closing. We have just over 325 investors now and hope that you might be one of those who joins this round before it closes. #AMR #Health
Don’t invest unless you’re prepared to lose all the money you invest.
europe.republic.com/metallobio/s...

An insidious impact of #AMR is the burden it places on healthcare systems. Simple infections can become serious medical care issues. Our new medications would not only treat patients, but will free up precious/costly healthcare resources, and specialist medical and support staff. #invest #health

Without effective antibiotics surgical
procedures and treatment of many diseases
will become almost impossible. What once were
treatable infections could become life
threatening. MetalloBio is working to
meet this global challenge through its
novel paradigm in antibiotics design. #AMR
#Worldhealth

Current antibiotics are all closely related. This means that bacteria are able to quickly evolve resistance to them. MetalloBio compounds rapidly stop bacterial growth, preventing them from developing antibiotic resistance and treating the infection. #AMR #WorldHealth

MetalloBio Webinar- Friday 29 November 2024 at 15:00
Engage directly with Mike (CEO) and Jim (CSO) as they present MetalloBio’s business plan, route to investment return and the company’s science.
Contact edie.john@metallobio.com to reserve a place. Registration closes at 18:00 on Thursday, 28th.

As #WAAW comes to a close MetalloBio wishes to focus on the end goal. Each one of our collaborator's
work brings us closer to potential new treatments that, based on our technology, could address untreatable
infections due to one of the biggest risks to global health, antimicrobial resistance. #AMR

Dr Bernardino de la Serna conducts notably multidisciplinary research, working with an incredible
background of knowledge, his skill in microscopy has captured images of bacteria engaging with Metallic
bio’s antibiotic drug candidates, showing the phenomena that led to rapid death. #WAAW #AMR

These Senior Lecturers based at The University of Sheffield have been working with us, testing
whether our compounds can be incorporated into 3D printing inks. The synergy of their work raises the
possibility that surgical prostheses using MetalloBio compounds can be used in reconstructive surgery.

Dr Adam Varney’s research focuses on antimicrobial drug testing and development. Through his extensive collaborations he tests and discovers mechanisms of action for antimicrobials. Dr Varney’s research has provided MetalloBio with insight into exactly how our compounds kill bacteria. #WAAW #AMR

Dr McLean’s work focuses on the microbial colonisation of medical device materials, and evaluating the efficacy of new approaches in its prevention. Her work regarding the characterisation of antimicrobial drugs as part of the development pipeline has been hugely important during our collaboration.

Professor Frederik Claeyssens’ work focuses on laser processing of biomaterials. Due to his extensive knowledge and research on this topic his advice to MetalloBio on extremely complex medical device coatings is indispensable whilst we navigate this highly specialised field. #WAAW #AMR

Professor Jim A Thomas is one of the co-founders of MetalloBio. Along with his PHD student Kirsty Smitten, Professor Thomas first identified the potential of the antimicrobial compounds that are being developed by MetalloBio. His wealth of knowledge is invaluable in our research. #AMR #WAAW2024